FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.
Zacks·4d ago
More News
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
Zacks·5d ago
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
Here is how Cardinal Health (CAH) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
Zacks·5d ago
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
Zacks·10d ago
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
Zacks·10d ago
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.
Zacks·11d ago
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
Zacks·14d ago
Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·14d ago
Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·17d ago
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.